Prognostic role of initial pan-endoscopic tumor length at diagnosis in operable esophageal squamous cell carcinoma undergoing esophagectomy with or without neoadjuvant concurrent chemoradiotherapy
机构:[1]Natl Yang Ming Univ, Fac Med, Taipei, Taiwan;[2]Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan;[3]Feng Yuan Hosp, Minist Hlth & Welf, Div Thorac Surg, Taichung, Taiwan;[4]Koo Fdn Sun Yat Sen Canc Ctr, Div Thorac Surg, 125 Lih Der Rd, Taipei 112, Taiwan;中山大学肿瘤防治中心[5]Far Eastern Mem Hosp, Div Thorac Surg, New Taipei, Taiwan;[6]Natl Def Univ, Taipei, Taiwan;[7]Koo Fdn Sun Yat Sen Canc Ctr, Psychiat Div, Taipei, Taiwan;中山大学肿瘤防治中心[8]Koo Fdn Sun Yat Sen Canc Ctr, Dept Radiat Oncol, Taipei, Taiwan;临床科室放疗科中山大学肿瘤防治中心[9]Koo Fdn Sun Yat Sen Canc Ctr, Dept Hematol & Med Oncol, Taipei, Taiwan;临床科室内科中山大学肿瘤防治中心[10]Koo Fdn Sun Yat Sen Canc Ctr, Dept Pathol, Taipei, Taiwan临床科室病理科中山大学肿瘤防治中心
Background: The objective of this study was to appraise the prognostic role of initial pan-endoscopic tumor length at diagnosis within or between operable esophageal squamous cell carcinoma (ESCC) undergoing upfront esophagectomy or neoadjuvant concurrent chemoradiotherapy (nCCRT) followed by esophagectomy. Methods: Between Jan 2001 and Dec 2013 in Koo-Foundation Sun Yat-sen Cancer Center in Taiwan, 101 ESCC patients who underwent upfront esophagectomy (surgery group) and 128 nCCRT followed by esophagectomy (nCCRT-surgery group) were retrospectively collected. Prognostic variables, including initial pan-endoscopic tumor length at diagnosis (sub-grouped <= 3, 3-5 and >5 cm), status of circumferential resection margin (CRM), and pathological T/N/M-status and cancer stage, were appraised within or between surgery and nCCRT-surgery groups. Results: Within surgery group, longer initial pan-endoscopic tumor length at diagnosis (= 3, 3-5 and >5 cm; HR = 1.000, 1.688 and 4.165; P=0.007) was an independent prognostic factor that correlated with advanced T/N/M-status, late cancer stage, and CRM invasion (all's P<0.001). Based on the initial panendoscopic tumor length at diagnosis = 3, 3-5 and >5 cm, nCCRT-surgery group had a poorer (P=0.039), similar (P=0.447) and better (P<0.001) survivals than did surgery group, respectively. For those with initial pan-endoscopic tumor length at diagnosis >5 cm, nCCRT-surgery group had more percentage of T0/N0status and stage 0 (all's P<0.05), and fewer rate of CRM invasion (P=0.036) than did surgery group. Conclusions: Initial pan-endoscopic tumor length at diagnosis could be a criterion to select proper ESCC cases for nCCRT followed by esophagectomy to improve survival and reduce CRM invasion.
语种:
外文
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2017]版:
大类|4 区医学
小类|4 区呼吸系统
最新[2023]版:
大类|3 区医学
小类|4 区呼吸系统
第一作者:
第一作者机构:[1]Natl Yang Ming Univ, Fac Med, Taipei, Taiwan;[2]Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan;[3]Feng Yuan Hosp, Minist Hlth & Welf, Div Thorac Surg, Taichung, Taiwan;[4]Koo Fdn Sun Yat Sen Canc Ctr, Div Thorac Surg, 125 Lih Der Rd, Taipei 112, Taiwan;
通讯作者:
通讯机构:[1]Natl Yang Ming Univ, Fac Med, Taipei, Taiwan;[4]Koo Fdn Sun Yat Sen Canc Ctr, Div Thorac Surg, 125 Lih Der Rd, Taipei 112, Taiwan;
推荐引用方式(GB/T 7714):
Lin Chen-Sung,Liu Chao-Yu,Cheng Chih-Tao,et al.Prognostic role of initial pan-endoscopic tumor length at diagnosis in operable esophageal squamous cell carcinoma undergoing esophagectomy with or without neoadjuvant concurrent chemoradiotherapy[J].JOURNAL OF THORACIC DISEASE.2017,9(9):3193-3207.doi:10.21037/jtd.2017.08.108.
APA:
Lin, Chen-Sung,Liu, Chao-Yu,Cheng, Chih-Tao,Tsai, Yu-Chen,Chiou, Lun-Wei...&Shih, Chih-Hsun.(2017).Prognostic role of initial pan-endoscopic tumor length at diagnosis in operable esophageal squamous cell carcinoma undergoing esophagectomy with or without neoadjuvant concurrent chemoradiotherapy.JOURNAL OF THORACIC DISEASE,9,(9)
MLA:
Lin, Chen-Sung,et al."Prognostic role of initial pan-endoscopic tumor length at diagnosis in operable esophageal squamous cell carcinoma undergoing esophagectomy with or without neoadjuvant concurrent chemoradiotherapy".JOURNAL OF THORACIC DISEASE 9..9(2017):3193-3207